IL-25 contributes to lung fibrosis by directly acting on alveolar epithelial cells and fibroblasts
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-25 contributes to lung fibrosis by directly acting on alveolar epithelial cells and fibroblasts
Authors
Keywords
-
Journal
EXPERIMENTAL BIOLOGY AND MEDICINE
Volume -, Issue -, Pages 153537021984382
Publisher
SAGE Publications
Online
2019-04-18
DOI
10.1177/1535370219843827
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets
- (2018) Justin C. Hewlett et al. MATRIX BIOLOGY
- The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis
- (2018) Awen Menou et al. MATRIX BIOLOGY
- Idiopathic Pulmonary Fibrosis
- (2018) David J. Lederer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histopathological Correlations between Mediastinal Fat-Associated Lymphoid Clusters and the Development of Lung Inflammation and Fibrosis following Bleomycin Administration in Mice
- (2018) Yaser Hosny Ali Elewa et al. Frontiers in Immunology
- Nicorandil ameliorates pulmonary inflammation and fibrosis in a rat model of silicosis
- (2018) Dalia H. El-Kashef INTERNATIONAL IMMUNOPHARMACOLOGY
- Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis
- (2017) A Tomaru et al. GENE THERAPY
- IL-25 in allergic inflammation
- (2017) Miao Xu et al. IMMUNOLOGICAL REVIEWS
- IL-25 Could Be Involved in the Development of Allergic Rhinitis Sensitized to House Dust Mite
- (2017) Dae Woo Kim et al. MEDIATORS OF INFLAMMATION
- Upregulation of interleukin-33 and thymic stromal lymphopoietin levels in the lungs of idiopathic pulmonary fibrosis
- (2017) Jong-Uk Lee et al. BMC Pulmonary Medicine
- Idiopathic pulmonary fibrosis
- (2017) Fernando J. Martinez et al. Nature Reviews Disease Primers
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis
- (2015) Hyun-Woo Shin et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Characteristics of IL-25 and allergen-induced airway fibrosis in a murine model of asthma
- (2015) Xiujuan Yao et al. RESPIROLOGY
- Direct comparison of the dynamics of IL-25- and ‘allergen’-induced airways inflammation, remodelling and hypersensitivity in a murine asthma model
- (2014) X. J. Yao et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis
- (2013) Norihiko Sakai et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Administration of Bleomycin via the Oropharyngeal Aspiration Route Leads to Sustained Lung Fibrosis in Mice and Rats as Quantified by UTE-MRI and Histology
- (2013) Christine Egger et al. PLoS One
- IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis
- (2013) E. Hams et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
- (2011) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis
- (2010) Amber L. Degryse et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats
- (2010) Kenji Adachi et al. JOURNAL OF TOXICOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started